The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.
Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician*. Potential patient groups include, but are not limited to, those with platinum-resistant/refractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic/recurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade/undifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.
Patients may be on active cancer treatment, about to commence active cancer treatment or under observation/palliative care.
Age ≥ 18 years
Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).
Unable to be comply with the protocol.
A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
Participation in another clinical trial.
Age ≥ 18 years
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Lead sponsor
Australia New Zealand Gynaecological Oncology Group
Collaborator